Compounds > metformin
Page last updated: 2024-10-30

metformin and Cerebral Ischemia

metformin has been researched along with Cerebral Ischemia in 33 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"We aimed to assess the feasibility, safety and effects on glucose metabolism of metformin or sitagliptin in patients with transient ischaemic attack (TIA) or minor ischaemic stroke and IGT."9.41Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance. ( Brouwers, PJAM; den Hertog, H; Dippel, DWJ; Koudstaal, P; Lingsma, H; Mulder, LJMM; Osei, E; Zandbergen, A, 2021)
"Preclinical studies have shown that metformin has neuroprotective actions in stroke."8.31Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study. ( Dang, M; Feng, Y; Jian, Y; Li, T; Li, Y; Lu, J; Lu, Z; Wang, H; Wang, X; Yang, Y; Zhang, G; Zhang, L; Zhang, Y; Zhao, L, 2023)
"In this study, we showed that pre-stroke metformin use was associated with favorable outcome after acute ischemic stroke in patients with diabetes mellitus type 2."8.12Effect of metformin on outcome after acute ischemic stroke in patients with type 2 diabetes mellitus. ( den Hertog, HM; Haalboom, M; Heijmans, E; Kersten, CJBA; Knottnerus, ILH; Zandbergen, AAM, 2022)
"This study is to analyze the neuroprotective effects of long-term metformin (Met) preconditioning on rats with ischemic brain injuries and the related mechanisms."8.02Neuroprotective Effects of Long-Term Metformin Preconditioning on Rats with Ischemic Brain Injuries. ( Guo, H; Liu, Y; Liu, Z; Pei, T; Ruan, C; Wang, A; Wang, L; Wang, S; Yang, D; Zhang, Z, 2021)
"Administration of metformin in DM patients prior to stroke onset may be associated with reduced neurological severity and improved acute-phase therapy outcomes."7.83Impact of Metformin on the Severity and Outcomes of Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus. ( Kuwashiro, T; Mima, Y; Nakamura, A; Okada, Y; Tsurusaki, Y; Wakugawa, Y; Yasaka, M, 2016)
"Accumulating evidence suggests that chronic metformin preconditioning offers potent neuroprotective effects against ischemic stroke."7.81Chronic Metformin Preconditioning Provides Neuroprotection via Suppression of NF-κB-Mediated Inflammatory Pathway in Rats with Permanent Cerebral Ischemia. ( Cao, L; Ding, ZZ; Jiang, T; Tan, L; Tan, MS; Wang, HF; Yu, JT; Zhang, QQ; Zhu, XC, 2015)
"Here, we have investigated the effect of metformin pretreatment in the rat models of global cerebral ischemia."7.80Activation of AMP-activated protein kinase by metformin protects against global cerebral ischemia in male rats: interference of AMPK/PGC-1α pathway. ( Ashabi, G; Goudarzvand, M; Khalaj, L; Khodagholi, F; Nasiri, M, 2014)
" Paradoxically, the clinical use of an AMPK activator metformin reduces the incidence of stroke."7.80Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. ( Cheng, J; Jia, J; Jin, Q; Liu, Y; Qin, Z; Wang, X; Wei, S; Wu, J; Zhen, X; Zhou, X, 2014)
"Metformin was administered to rats orally by gavage 500 mg/kg once daily for one week before induction of cerebral ischemia (rats were subjected to 30 min of ischemia before decapitation) and ischemia/reperfusion (rats were subjected to 30 min of ischemia then 60 minutes of reperfusion before decapitation)."7.80Modulation of the oxidative stress by metformin in the cerebrum of rats exposed to global cerebral ischemia and ischemia/reperfusion. ( Abd-Elsameea, AA; Mohamed, AM; Moustaf, AA, 2014)
"Hyperglycemia is a known exacerbating factor in ischemic stroke."6.47[Effectiveness of metformin in prevention of development of hyperglycemia and neuronal damage caused by ischemic stress]. ( Fujita-Hamabe, W; Harada, S; Tokuyama, S, 2011)
"Metformin (MET) has been the subject of many classic studies in possessing antiapoptotic, anti-inflammatory, antioxidation activities and antiviral."5.72Metformin protects against pericyte apoptosis and promotes neurogenesis through suppressing JNK p38 MAPK signalling activation in ischemia/reperfusion injury. ( Cui, K; Fu, X; Liu, C; Lu, Z; Man, J; Wang, J; Zhang, D; Zhang, Z, 2022)
"Metformin (Met) is a commonly used drug in the treatment of type 2 diabetes."5.62Neuroprotective effects of metformin on cerebral ischemia-reperfusion injury by regulating PI3K/Akt pathway. ( Gao, J; Guo, H; Li, X; Liu, Z; Lv, H; Ruan, C; Wang, Y; Yan, J, 2021)
"Rats underwent cerebral ischemia/reperfusion and MET was administered orally at doses of 100 and 200 mg/kg for 56 days."5.56Long-term metformin therapy improves neurobehavioral functions and antioxidative activity after cerebral ischemia/reperfusion injury in rats. ( Allahtavakoli, M; Esmaeil-Moghaddam, S; Fatemi, I; Hakimizadeh, E; Kaeidi, A; Pak-Hashemi, M; Saeed-Askari, P, 2020)
"Stroke is a leading cause of mortality and disability worldwide."5.46Involvement of arterial baroreflex and nicotinic acetylcholine receptor α7 subunit pathway in the protection of metformin against stroke in stroke-prone spontaneously hypertensive rats. ( Guo, JM; Liu, AJ; Niu, XC; Shu, H; Su, DF; Wang, L; Xu, JJ; Zhang, L; Zhang, Y; Zhu, DQ, 2017)
"Metformin was pretreated for 2 weeks and CC administrated half an hour before global cerebral ischemia."5.42Metformin improves anxiety-like behaviors through AMPK-dependent regulation of autophagy following transient forebrain ischemia. ( Ashabi, G; Badavi, M; Farbood, Y; Khalaj, L; Khodagholi, F; Sarkaki, A, 2015)
"Met attenuated BBB disruption and reactive hyperemia in tGCI rats compared with the untreated I/R rats (p < 0."5.42Targeting Adenosine Monophosphate-Activated Protein Kinase by Metformin Adjusts Post-Ischemic Hyperemia and Extracellular Neuronal Discharge in Transient Global Cerebral Ischemia. ( Ashabi, G; Badavi, M; Farbood, Y; Khalaj, L; Khodagholi, F; Sarkaki, A, 2015)
"We aimed to assess the feasibility, safety and effects on glucose metabolism of metformin or sitagliptin in patients with transient ischaemic attack (TIA) or minor ischaemic stroke and IGT."5.41Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance. ( Brouwers, PJAM; den Hertog, H; Dippel, DWJ; Koudstaal, P; Lingsma, H; Mulder, LJMM; Osei, E; Zandbergen, A, 2021)
"Preclinical studies have shown that metformin has neuroprotective actions in stroke."4.31Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study. ( Dang, M; Feng, Y; Jian, Y; Li, T; Li, Y; Lu, J; Lu, Z; Wang, H; Wang, X; Yang, Y; Zhang, G; Zhang, L; Zhang, Y; Zhao, L, 2023)
"In this study, we showed that pre-stroke metformin use was associated with favorable outcome after acute ischemic stroke in patients with diabetes mellitus type 2."4.12Effect of metformin on outcome after acute ischemic stroke in patients with type 2 diabetes mellitus. ( den Hertog, HM; Haalboom, M; Heijmans, E; Kersten, CJBA; Knottnerus, ILH; Zandbergen, AAM, 2022)
"This study is to analyze the neuroprotective effects of long-term metformin (Met) preconditioning on rats with ischemic brain injuries and the related mechanisms."4.02Neuroprotective Effects of Long-Term Metformin Preconditioning on Rats with Ischemic Brain Injuries. ( Guo, H; Liu, Y; Liu, Z; Pei, T; Ruan, C; Wang, A; Wang, L; Wang, S; Yang, D; Zhang, Z, 2021)
" Initiators of metformin and sulfonylurea monotherapy were matched on high-dimensional propensity score, and Cox proportional hazards models were used to compare the rate of cardiovascular events (myocardial infarction, ischaemic stroke, cardiovascular death, and all-cause mortality) with sulfonylureas vs metformin."3.91Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study. ( Azoulay, L; Douros, A; Filion, KB; Suissa, S; Yin, H; Yu, OH, 2019)
"Administration of metformin in DM patients prior to stroke onset may be associated with reduced neurological severity and improved acute-phase therapy outcomes."3.83Impact of Metformin on the Severity and Outcomes of Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus. ( Kuwashiro, T; Mima, Y; Nakamura, A; Okada, Y; Tsurusaki, Y; Wakugawa, Y; Yasaka, M, 2016)
"Accumulating evidence suggests that chronic metformin preconditioning offers potent neuroprotective effects against ischemic stroke."3.81Chronic Metformin Preconditioning Provides Neuroprotection via Suppression of NF-κB-Mediated Inflammatory Pathway in Rats with Permanent Cerebral Ischemia. ( Cao, L; Ding, ZZ; Jiang, T; Tan, L; Tan, MS; Wang, HF; Yu, JT; Zhang, QQ; Zhu, XC, 2015)
"Here, we have investigated the effect of metformin pretreatment in the rat models of global cerebral ischemia."3.80Activation of AMP-activated protein kinase by metformin protects against global cerebral ischemia in male rats: interference of AMPK/PGC-1α pathway. ( Ashabi, G; Goudarzvand, M; Khalaj, L; Khodagholi, F; Nasiri, M, 2014)
" Paradoxically, the clinical use of an AMPK activator metformin reduces the incidence of stroke."3.80Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke. ( Cheng, J; Jia, J; Jin, Q; Liu, Y; Qin, Z; Wang, X; Wei, S; Wu, J; Zhen, X; Zhou, X, 2014)
"Metformin was administered to rats orally by gavage 500 mg/kg once daily for one week before induction of cerebral ischemia (rats were subjected to 30 min of ischemia before decapitation) and ischemia/reperfusion (rats were subjected to 30 min of ischemia then 60 minutes of reperfusion before decapitation)."3.80Modulation of the oxidative stress by metformin in the cerebrum of rats exposed to global cerebral ischemia and ischemia/reperfusion. ( Abd-Elsameea, AA; Mohamed, AM; Moustaf, AA, 2014)
"Hyperglycemia is a known exacerbating factor in ischemic stroke."2.47[Effectiveness of metformin in prevention of development of hyperglycemia and neuronal damage caused by ischemic stress]. ( Fujita-Hamabe, W; Harada, S; Tokuyama, S, 2011)
" Long-term use of metformin, an AMPK activator, was previously reported to be neuroprotective, as it promotes behavioral improvement and angiogenesis following an acute ischemic injury of the brain."1.91Activated AMPK Protects Against Chronic Cerebral Ischemia in Bilateral Carotid Artery Stenosis Mice. ( Cai, B; Xie, W; Zeng, Y; Zheng, Y, 2023)
"Metformin (MET) has been the subject of many classic studies in possessing antiapoptotic, anti-inflammatory, antioxidation activities and antiviral."1.72Metformin protects against pericyte apoptosis and promotes neurogenesis through suppressing JNK p38 MAPK signalling activation in ischemia/reperfusion injury. ( Cui, K; Fu, X; Liu, C; Lu, Z; Man, J; Wang, J; Zhang, D; Zhang, Z, 2022)
"Metformin (Met) is a commonly used drug in the treatment of type 2 diabetes."1.62Neuroprotective effects of metformin on cerebral ischemia-reperfusion injury by regulating PI3K/Akt pathway. ( Gao, J; Guo, H; Li, X; Liu, Z; Lv, H; Ruan, C; Wang, Y; Yan, J, 2021)
"Rats underwent cerebral ischemia/reperfusion and MET was administered orally at doses of 100 and 200 mg/kg for 56 days."1.56Long-term metformin therapy improves neurobehavioral functions and antioxidative activity after cerebral ischemia/reperfusion injury in rats. ( Allahtavakoli, M; Esmaeil-Moghaddam, S; Fatemi, I; Hakimizadeh, E; Kaeidi, A; Pak-Hashemi, M; Saeed-Askari, P, 2020)
"Platelet thrombosis is the main pathogeny resulting in the low curability of ischemic stroke, a leading cause of mortality and disability worldwide."1.56Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke. ( Chen, Z; He, Y; Huang, W; Ji, C; Lee, KH; Li, S; Li, Y; Ming, Y; Morris-Natschke, SL; Niu, H; Wei, Z; Xin, G; Xing, Z; Yang, X; Yu, K; Zhang, B; Zhang, J; Zhang, X, 2020)
"Metformin 200 mg/kg was given intravenously to the cardiac I/R group (n = 10/group), either during ischemia (D-MET) or at the onset of reperfusion (R-MET)."1.56Metformin preferentially provides neuroprotection following cardiac ischemia/reperfusion in non-diabetic rats. ( Apaijai, N; Arunsak, B; Benjanuwattra, J; Chattipakorn, N; Chattipakorn, SC; Chunchai, T; Jaiwongkam, T; Kerdphoo, S; Wongsuchai, S, 2020)
"Sudden cardiac arrest (CA) often results in severe injury to the brain, and neuroprotection after CA has proved to be difficult to achieve."1.48Metformin Improves Neurologic Outcome Via AMP-Activated Protein Kinase-Mediated Autophagy Activation in a Rat Model of Cardiac Arrest and Resuscitation. ( Gu, Y; Hu, Y; Huang, K; Ji, Z; Liu, K; Pan, S; Zhu, J, 2018)
"Stroke is a leading cause of mortality and disability worldwide."1.46Involvement of arterial baroreflex and nicotinic acetylcholine receptor α7 subunit pathway in the protection of metformin against stroke in stroke-prone spontaneously hypertensive rats. ( Guo, JM; Liu, AJ; Niu, XC; Shu, H; Su, DF; Wang, L; Xu, JJ; Zhang, L; Zhang, Y; Zhu, DQ, 2017)
"Pretreatment with metformin in I/R animals reduced levels of pro-BDNF compared with the I/R group (p < 0."1.43Metformin pretreatment enhanced learning and memory in cerebral forebrain ischaemia: the role of the AMPK/BDNF/P70SK signalling pathway. ( Ashabi, G; Ghadernezhad, N; Khalaj, L; Mirmasoumi, M; Pazoki-Toroudi, H, 2016)
"Met attenuated BBB disruption and reactive hyperemia in tGCI rats compared with the untreated I/R rats (p < 0."1.42Targeting Adenosine Monophosphate-Activated Protein Kinase by Metformin Adjusts Post-Ischemic Hyperemia and Extracellular Neuronal Discharge in Transient Global Cerebral Ischemia. ( Ashabi, G; Badavi, M; Farbood, Y; Khalaj, L; Khodagholi, F; Sarkaki, A, 2015)
"Metformin was pretreated for 2 weeks and CC administrated half an hour before global cerebral ischemia."1.42Metformin improves anxiety-like behaviors through AMPK-dependent regulation of autophagy following transient forebrain ischemia. ( Ashabi, G; Badavi, M; Farbood, Y; Khalaj, L; Khodagholi, F; Sarkaki, A, 2015)
"We identified 4817 stroke patients with type 2 diabetes mellitus."1.38Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study. ( Horsdal, HT; Johnsen, SP; Mehnert, F; Rungby, J, 2012)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's20 (60.61)24.3611
2020's13 (39.39)2.80

Authors

AuthorsStudies
Xin, G1
Ming, Y1
Ji, C1
Wei, Z1
Li, S2
Morris-Natschke, SL1
Zhang, X5
Yu, K2
Li, Y9
Zhang, B1
Zhang, J4
Xing, Z1
He, Y3
Chen, Z1
Yang, X3
Niu, H1
Lee, KH1
Huang, W2
Ruan, C2
Guo, H2
Gao, J1
Wang, Y4
Liu, Z4
Yan, J1
Li, X12
Lv, H1
Osei, E1
Zandbergen, A1
Brouwers, PJAM1
Mulder, LJMM1
Koudstaal, P1
Lingsma, H1
Dippel, DWJ1
den Hertog, H1
Liu, C4
Zhang, D3
Lu, Z4
Man, J1
Zhang, Z2
Fu, X1
Cui, K1
Wang, J5
Kersten, CJBA1
Knottnerus, ILH1
Heijmans, E1
Haalboom, M1
Zandbergen, AAM1
den Hertog, HM1
Xie, W3
Zeng, Y3
Zheng, Y4
Cai, B3
Jian, Y3
Wang, H5
Zhao, L3
Li, T3
Zhang, L6
Wang, X11
Zhang, Y8
Dang, M3
Lu, J5
Feng, Y3
Yang, Y4
Zhang, G3
Li, Z3
Shi, X2
Ding, J1
Benjanuwattra, J1
Apaijai, N1
Chunchai, T1
Kerdphoo, S1
Jaiwongkam, T1
Arunsak, B1
Wongsuchai, S1
Chattipakorn, N2
Chattipakorn, SC2
Fatemi, I1
Saeed-Askari, P1
Hakimizadeh, E1
Kaeidi, A1
Esmaeil-Moghaddam, S1
Pak-Hashemi, M1
Allahtavakoli, M1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y3
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Zhang, E1
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Zhou, X3
Wang, W1
Wang, S3
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L3
Zhu, J3
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Wu, X1
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J2
Kong, X1
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Luo, Z1
Mei, Z1
Yao, Y1
Liang, C1
Yang, H1
Song, Y1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Liu, Y6
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Wang, Q2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Gao, F1
Qi, Y1
Lu, H1
Cai, X1
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Hu, X1
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y2
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Wu, J2
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D2
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q2
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Sharma, S1
Nozohouri, S1
Vaidya, B1
Abbruscato, T1
Wang, A1
Pei, T1
Liu, K1
Huang, K1
Gu, Y1
Hu, Y1
Pan, S1
Ji, Z1
Yuan, R1
Zhen, F1
Lai, Q1
Hu, P1
Fan, H1
Yao, R1
Leech, T1
Filion, KB1
Douros, A1
Azoulay, L1
Yin, H1
Yu, OH1
Suissa, S1
Harada, S3
Yamazaki, Y1
Tokuyama, S3
Ashabi, G5
Khodagholi, F4
Khalaj, L5
Goudarzvand, M2
Nasiri, M1
Jiang, T2
Yu, JT2
Zhu, XC2
Wang, HF2
Tan, MS2
Cao, L2
Zhang, QQ2
Gao, L1
Shi, JQ1
Zhang, YD1
Tan, L2
Jin, Q1
Wei, S1
Qin, Z1
Jia, J1
Zhen, X1
Ding, ZZ1
Abd-Elsameea, AA1
Moustaf, AA1
Mohamed, AM1
Sarkaki, A3
Farbood, Y3
Badavi, M3
Mima, Y1
Kuwashiro, T1
Yasaka, M1
Tsurusaki, Y1
Nakamura, A1
Wakugawa, Y1
Okada, Y1
Ghadernezhad, N1
Pazoki-Toroudi, H1
Mirmasoumi, M1
Ge, XH1
Zhu, GJ1
Geng, DQ1
Zhang, HZ1
He, JM1
Guo, AZ1
Ma, LL1
Yu, DH1
Zareh Shahamati, S1
Guo, JM1
Niu, XC1
Shu, H1
Su, DF1
Liu, AJ1
Zhu, DQ1
Xu, JJ1
Fujita-Hamabe, W2
Horsdal, HT1
Mehnert, F1
Rungby, J1
Johnsen, SP1

Reviews

5 reviews available for metformin and Cerebral Ischemia

ArticleYear
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke.
    Life sciences, 2021, Jun-01, Volume: 274

    Topics: Aging; Animals; Brain Ischemia; Drug Repositioning; Humans; Hypoglycemic Agents; Metformin; Neurodeg

2021
The beneficial roles of metformin on the brain with cerebral ischaemia/reperfusion injury.
    Pharmacological research, 2019, Volume: 146

    Topics: Animals; Apoptosis; Brain; Brain Ischemia; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin

2019
[Search of new therapeutics for cerebral infarction--post-ischemic glucose intolerance induced by cerebral neuronal damage and the involvement of the communication system between the brain and peripheral tissues].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2013, Volume: 142, Issue:1

    Topics: Animals; Brain; Brain Ischemia; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin; Intracell

2013
[Effectiveness of metformin in prevention of development of hyperglycemia and neuronal damage caused by ischemic stress].
    Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2011, Volume: 131, Issue:4

    Topics: Administration, Oral; AMP-Activated Protein Kinases; Animals; Brain; Brain Ischemia; Disease Models,

2011

Trials

2 trials available for metformin and Cerebral Ischemia

ArticleYear
Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance.
    BMJ open, 2021, 09-16, Volume: 11, Issue:9

    Topics: Blood Glucose; Brain Ischemia; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combina

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021

Other Studies

27 other studies available for metformin and Cerebral Ischemia

ArticleYear
Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke.
    European journal of medicinal chemistry, 2020, Aug-15, Volume: 200

    Topics: Administration, Oral; Animals; Biguanides; Brain Ischemia; Dose-Response Relationship, Drug; Male; M

2020
Neuroprotective effects of metformin on cerebral ischemia-reperfusion injury by regulating PI3K/Akt pathway.
    Brain and behavior, 2021, Volume: 11, Issue:10

    Topics: Animals; Apoptosis; Brain Ischemia; Diabetes Mellitus, Type 2; Infarction, Middle Cerebral Artery; M

2021
Metformin protects against pericyte apoptosis and promotes neurogenesis through suppressing JNK p38 MAPK signalling activation in ischemia/reperfusion injury.
    Neuroscience letters, 2022, 07-13, Volume: 783

    Topics: Animals; Apoptosis; Brain Ischemia; Caspase 3; Infarction, Middle Cerebral Artery; MAP Kinase Signal

2022
Effect of metformin on outcome after acute ischemic stroke in patients with type 2 diabetes mellitus.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2022, Volume: 31, Issue:9

    Topics: Brain Ischemia; Diabetes Mellitus, Type 2; Humans; Ischemic Stroke; Metformin; Stroke; Treatment Out

2022
Activated AMPK Protects Against Chronic Cerebral Ischemia in Bilateral Carotid Artery Stenosis Mice.
    Cellular and molecular neurobiology, 2023, Volume: 43, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Brain Ischemia; Carotid Stenosis; Disease Models, Animal; Ma

2023
Activated AMPK Protects Against Chronic Cerebral Ischemia in Bilateral Carotid Artery Stenosis Mice.
    Cellular and molecular neurobiology, 2023, Volume: 43, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Brain Ischemia; Carotid Stenosis; Disease Models, Animal; Ma

2023
Activated AMPK Protects Against Chronic Cerebral Ischemia in Bilateral Carotid Artery Stenosis Mice.
    Cellular and molecular neurobiology, 2023, Volume: 43, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Brain Ischemia; Carotid Stenosis; Disease Models, Animal; Ma

2023
Activated AMPK Protects Against Chronic Cerebral Ischemia in Bilateral Carotid Artery Stenosis Mice.
    Cellular and molecular neurobiology, 2023, Volume: 43, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Brain Ischemia; Carotid Stenosis; Disease Models, Animal; Ma

2023
Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023, Volume: 44, Issue:3

    Topics: Brain Ischemia; Diabetes Mellitus, Type 2; Humans; Ischemic Stroke; Metformin; Retrospective Studies

2023
Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023, Volume: 44, Issue:3

    Topics: Brain Ischemia; Diabetes Mellitus, Type 2; Humans; Ischemic Stroke; Metformin; Retrospective Studies

2023
Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023, Volume: 44, Issue:3

    Topics: Brain Ischemia; Diabetes Mellitus, Type 2; Humans; Ischemic Stroke; Metformin; Retrospective Studies

2023
Metformin treatment and acute ischemic stroke outcomes in patients with type 2 diabetes: a retrospective cohort study.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023, Volume: 44, Issue:3

    Topics: Brain Ischemia; Diabetes Mellitus, Type 2; Humans; Ischemic Stroke; Metformin; Retrospective Studies

2023
Metformin attenuates white matter injury and cognitive impairment induced by chronic cerebral hypoperfusion.
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2023, Volume: 43, Issue:2_suppl

    Topics: Animals; Brain Ischemia; Carotid Stenosis; Cognitive Dysfunction; Dementia, Vascular; Diabetes Melli

2023
Metformin preferentially provides neuroprotection following cardiac ischemia/reperfusion in non-diabetic rats.
    Biochimica et biophysica acta. Molecular basis of disease, 2020, 10-01, Volume: 1866, Issue:10

    Topics: Administration, Intravenous; Amyloid beta-Peptides; Animals; Apoptosis; Brain; Brain Ischemia; Dendr

2020
Long-term metformin therapy improves neurobehavioral functions and antioxidative activity after cerebral ischemia/reperfusion injury in rats.
    Brain research bulletin, 2020, Volume: 163

    Topics: Animals; Antioxidants; Brain Ischemia; Dose-Response Relationship, Drug; Drug Administration Schedul

2020
Neuroprotective Effects of Long-Term Metformin Preconditioning on Rats with Ischemic Brain Injuries.
    European neurology, 2021, Volume: 84, Issue:3

    Topics: Animals; Apoptosis; Brain Injuries; Brain Ischemia; Humans; Infarction, Middle Cerebral Artery; Metf

2021
Metformin Improves Neurologic Outcome Via AMP-Activated Protein Kinase-Mediated Autophagy Activation in a Rat Model of Cardiac Arrest and Resuscitation.
    Journal of the American Heart Association, 2018, 06-12, Volume: 7, Issue:12

    Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Brain Ischemia; CA1 Region, Hippocampa

2018
Metformin reduces neuronal damage and promotes neuroblast proliferation and differentiation in a cerebral ischemia/reperfusion rat model.
    Neuroreport, 2019, 02-06, Volume: 30, Issue:3

    Topics: Animals; Astrocytes; Brain Ischemia; Cell Differentiation; Cell Proliferation; Disease Models, Anima

2019
Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:10

    Topics: Aged; Aged, 80 and over; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Databases, Factual

2019
Activation of AMP-activated protein kinase by metformin protects against global cerebral ischemia in male rats: interference of AMPK/PGC-1α pathway.
    Metabolic brain disease, 2014, Volume: 29, Issue:1

    Topics: Adenylate Kinase; Animals; Apoptosis; Brain; Brain Ischemia; Dose-Response Relationship, Drug; Drug

2014
Acute metformin preconditioning confers neuroprotection against focal cerebral ischaemia by pre-activation of AMPK-dependent autophagy.
    British journal of pharmacology, 2014, Volume: 171, Issue:13

    Topics: Adenine; AMP-Activated Protein Kinases; Animals; Apoptosis; Autophagy; Brain; Brain Ischemia; Diseas

2014
Improvement of functional recovery by chronic metformin treatment is associated with enhanced alternative activation of microglia/macrophages and increased angiogenesis and neurogenesis following experimental stroke.
    Brain, behavior, and immunity, 2014, Volume: 40

    Topics: AMP-Activated Protein Kinases; Angiogenesis Inducing Agents; Animals; Brain; Brain Ischemia; Infarct

2014
Chronic Metformin Preconditioning Provides Neuroprotection via Suppression of NF-κB-Mediated Inflammatory Pathway in Rats with Permanent Cerebral Ischemia.
    Molecular neurobiology, 2015, Volume: 52, Issue:1

    Topics: Acute Disease; Animals; Astrocytes; Brain; Brain Ischemia; Calcium-Binding Proteins; Cytokines; Glia

2015
Modulation of the oxidative stress by metformin in the cerebrum of rats exposed to global cerebral ischemia and ischemia/reperfusion.
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:16

    Topics: Animals; Brain Ischemia; Catalase; Cerebrum; Glutathione Peroxidase; Male; Malondialdehyde; Metformi

2014
Metformin improves anxiety-like behaviors through AMPK-dependent regulation of autophagy following transient forebrain ischemia.
    Metabolic brain disease, 2015, Volume: 30, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Anxiety; Autophagy; Brain Ischemia; Male; Metformin; Motor A

2015
Targeting Adenosine Monophosphate-Activated Protein Kinase by Metformin Adjusts Post-Ischemic Hyperemia and Extracellular Neuronal Discharge in Transient Global Cerebral Ischemia.
    Microcirculation (New York, N.Y. : 1994), 2015, Volume: 22, Issue:7

    Topics: AMP-Activated Protein Kinases; Animals; Blood-Brain Barrier; Brain Ischemia; Hyperemia; Male; Metfor

2015
Impact of Metformin on the Severity and Outcomes of Acute Ischemic Stroke in Patients with Type 2 Diabetes Mellitus.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016, Volume: 25, Issue:2

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Brain Ischemia; Diabetes Mellitus, Type 2; Fema

2016
Metformin pretreatment enhanced learning and memory in cerebral forebrain ischaemia: the role of the AMPK/BDNF/P70SK signalling pathway.
    Pharmaceutical biology, 2016, Volume: 54, Issue:10

    Topics: AMP-Activated Protein Kinases; Animals; Behavior, Animal; Brain Ischemia; Brain-Derived Neurotrophic

2016
Metformin protects the brain against ischemia/reperfusion injury through PI3K/Akt1/JNK3 signaling pathways in rats.
    Physiology & behavior, 2017, 03-01, Volume: 170

    Topics: Animals; Anxiety; Apoptosis; Brain Ischemia; CA1 Region, Hippocampal; Caspase 3; Cognition Disorders

2017
Subchronic metformin pretreatment enhances novel object recognition memory task in forebrain ischemia: behavioural, molecular, and electrophysiological studies.
    Canadian journal of physiology and pharmacology, 2017, Volume: 95, Issue:4

    Topics: AMP-Activated Protein Kinases; Animals; Brain Ischemia; Cognitive Dysfunction; Cyclic AMP Response E

2017
Involvement of arterial baroreflex and nicotinic acetylcholine receptor α7 subunit pathway in the protection of metformin against stroke in stroke-prone spontaneously hypertensive rats.
    European journal of pharmacology, 2017, Mar-05, Volume: 798

    Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Arteries; Baroreflex; Brain Ischemia; Cytokines; D

2017
RETRACTED: The importance of regulation of blood glucose levels through activation of peripheral 5'-AMP-activated protein kinase on ischemic neuronal damage.
    Brain research, 2010, 09-10, Volume: 1351

    Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Brain Ischemia; Enzyme Activation; Infarction

2010
Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:8

    Topics: Aged; Aged, 80 and over; Brain Ischemia; Denmark; Diabetes Mellitus, Type 2; Female; Follow-Up Studi

2012